These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 26339063)

  • 1. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
    Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
    J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
    Recordon-Pinson P; Raymond S; Bellecave P; Marcelin AG; Soulie C; Descamps D; Calvez V; Harrigan PR; Fleury H; Izopet J; Masquelier B;
    Antimicrob Agents Chemother; 2013 Feb; 57(2):930-5. PubMed ID: 23208718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
    Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
    Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
    J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of resistance and failure of treatment with maraviroc].
    Delgado R
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
    Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
    PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
    Nedellec R; Coetzer M; Lederman MM; Offord RE; Hartley O; Mosier DE
    PLoS One; 2011; 6(7):e22020. PubMed ID: 21760945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
    Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM; Kanmogne GD
    Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.